Anne de la Rochefordiere¹, Youlia Kirova¹, Severine Alran², Corine Plancher³, Virginie Fourchotte², Philippe Beuzeboc⁴, Vincent de Margerie², Peter Petrow⁵, Xavier Sastre-Garau⁶, Vincent Servois⁵, Suzy Scholl⁴, Paul Cottu⁴, Laurent Mignot⁴, Patricia de Cremoux⁶ and Remy Salmon²

¹Radiation Oncology, ²Surgery, ³Biostatistics, ⁴Medical Oncology, ⁵Radiology, ⁶Pathology, for Gynaecology Study Group of the Institut Curie, Paris, France.

Abstract

Objective: To evaluate the treatment results of patients (pts) with FIGO stage IB2, IIA, IIB cervical carcinoma (CC) treated with pre-operative radio-chemotherapy, followed by extended radical hysterectomy.

Methods: Retrospective study of 148 women treated to the Institut Curie for operable FIGO Stage IB2 to IIB, biopsy proved CC. Among them, 70 pts, median age 46 years, were treated using the same regimen associating primary radio-cisplatinum based chemotherapy, intracavitary LDR brachytherapy, followed by extended radical hysterectomy. Kaplan-Meier estimates were used to draw survival curves. Comparisons of survival distribution were assessed by the log-rank test.

Results: Complete histological local-regional response was obtained in 56% of the pts (n = 39). Residual macroscopic or microscopic disease in the cervix was observed in 28 pts (40%). All but one had in-situ microscopic residual CC. Lateral residual disease in the parametria was also present in 9 pts, all with residual CC. Pelvic lymph nodes were free from microscopic disease in 56 pts (80%). Eight of 55 (11%) radiological N0 patients had microscopic nodal involvement, as compared to 6/15 (40%) radiological N1 (p = 0.03). Seventeen pts (25%) had residual cervix disease but negative nodes. After median follow-up of 40 months (range, 8–141), 38/70 patients (54.1%) are still alive and free of disease, 6 (8.6%) alive with disease, and 11 (15.8%) patients were lost for follow-up but free of disease.

In conclusion: The treatment of locally advanced CC needs a new multidisciplinary diagnostic and treatment approach using new therapeutic arms to improve the survival and treatment tolerance among women presenting this disease.